molecules of the month


low α- M1R positive allosteric modulator

7.5 mg+ PO QD in Ph. II for Parkinson’s

from eval. of M1R PAMs w/ low cooperativity

British Journal of Clinical Pharmacology

Takeda Pharmaceutical, Cambridge, USA

Chemical structure of TAK-071
1 min read

The Takeda brain-penetrant M1R positive allosteric modulator (PAM), TAK-071, was optimized for lower cooperativity (α) with the native ligand to theoretically reduce the side effect of diarrhea from M1R activation. In animal models, higher cooperativity on M1R was associated with diarrhea, while lower cooperativity led to a wider margin. In this first-in-human study, TAK-071 appears to safe and well tolerated in humans, with notably uncommon nausea, vomiting, or diarrhea effects typical of cholinergic agents. TAK-071 demonstrates a long half-life of ~46-60 h with excellent brain penetration at a low dose, which is impressive for a molecule containing a secondary alcohol and THP ring. A Ph. II trial for Parkinson’s appears to be actively enrolling (NCT04334317) with a sentinel dose of…

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: